Aspire Biopharma Holdings, Inc. ASBP
8.32
(0.38)
(4.37%)
as of 25 Sep
- Market cap
- $12.2M
- P/E
- 0.2×
Follow ASBP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.15 |
P/S ratio |
0.00 | 0.00 | 0.00 | 56.73 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.31) | (0.28) | (0.05) | (2.62) | |
P/B ratio |
0.00 | 0.00 | 0.04 | 0.47 | |
Price to Tangible BV |
0.00 | 0.00 | 0.04 | 0.47 | |
EV/Sales |
0.00 | 0.00 | 0.00 | (39.24) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.32) | (0.42) | 0.47 | 0.53 | |
EV/FCF |
(1.32) | (0.42) | 0.47 | 0.53 | |
Quick Ratio |
0.14 | 0.13 | 1.86 | 7.22 | |
Current Ratio |
0.17 | 0.17 | 2.26 | 7.99 | |
Net Debt/EBITDA |
(3.75) | 0.43 | 94.01 | 4.54 | |
Debt/Assets |
259.66% | 212.66% | 0.00% | 0.00% | |
Debt/Equity |
(0.54) | (0.44) | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF/Net income |
0.60 | 0.20 | 0.94 | 1.67 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10,942.11% | 2,325.58% | 1,044.72% | 370.05% | |
Selling, General and Administrative Expense of Revenue |
49,394.74% | 40,660.47% | 4,771.83% | 3,463.07% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 47.18% | 228.37% | |
Graham Net Nets |
(33.78) | (24.25) | 23.97 | 2.11 | |
Graham Number |
1,992.48 | 1,193.46 | 0.00 | 96.25 | |
Earnings Yield |
(7,693.36%) | (9,363.89%) | (1,017.41%) | 680.69% | |
Free Cash Flow Yield |
(1,035.68%) | (1,872.45%) | (3,847.87%) | (129.65%) | |
Revenue per Share |
0.05 | 0.09 | 0.18 | 0.06 | |
Operating CF per Share |
(26.79) | (18.63) | (19.39) | (2.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(26.79) | (18.63) | (19.39) | (2.04) | |
Cash per Share |
47.29 | 20.16 | 37.38 | 11.72 | |
Shareholders Equity per Share |
(278.33) | (128.04) | 24.69 | 11.33 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(278.33) | (128.04) | 24.69 | 11.33 | |
Free Cash Flow |
(1.10) | (0.93) | (3.04) | (2.12) | |
Working Capital |
(11.46) | (6.28) | 3.96 | 11.78 | |
Net Current Asset Value |
(11.47) | (6.38) | 3.87 | 11.68 | |
EV/EBIT |
0.00 | 0.00 | 0.53 | 0.52 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(97,394.74%) | (109,481.40%) | (11,348.24%) | (2,009.67%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.98 | 0.66 | 1.37 | 1.35 | |
Average Assets |
4.53 | 0.73 | 4.54 | 7.26 | |
Average Common Equity |
(8.99) | (3.96) | (2.04) | 1.07 |
Columns are period end dates